Multiple sclerosis (relapsing) - teriflunomide: evaluation report
01 - Pre-Meeting Briefing prepared by NICE
02 - Submission from the technology manufacturer Genzyme
03 - Patient Access Scheme submission from the technology manufacturer Genzyme
04 - NICE request to the manufacturer for clarification on their submission
05 - Manufacturer clarification response
06 - Consultee Submission - Multiple Sclerosis Society
07 - Consultee Submission - Multiple Sclerosis Trust
08 - Consultee Submission - Association of British Nurses
09 - Consultee Submission - United Kingdom Clinical Pharmacy Association
10 - Clinical expert personal perspective
11 - Clinical expert personal perspective
12 - Patient expert personal perspective
13 - Patient expert personal perspective
14 - Evidence Review Group Report prepared by York, Centre for Reviews and Dissemination and Centre for Health Economics
15 - Evidence Review Group erratum
16 - Evidence Review Group report - factual accuracy check
Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.
It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.
If you have any feedback on the new format please contact the Project Manager for this appraisal.
Multiple sclerosis (relapsing) - teriflunomide: evaluation report
18 September 2013 (12.56 Mb 26 sec) |
This page was last updated: 20 September 2013